Phages inject their genome in specific bacteria strains, replicate and burst out of them. Phages are a possible therapy against multi-drug-resistant bacteria.
Overview and Scope
Multidrug-resistant bacteria refer to strains of bacteria that have developed resistance to multiple types or classes of antibiotics. These bacteria are no longer susceptible to the effects of several different antibiotics that would typically be effective in treating bacterial infections. Multidrug-resistant organisms tend to occur in hospitals and medical care facilities when antibiotics are used for longer than necessary or when they are not needed.
Sizing and Forecast
The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $11.86 billion in 2023 to $12.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.
The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $16.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report
Segmentation & Regional Insights
The multidrug resistant bacteria market covered in this report is segmented –
1) By Disease: Urinary Tract Infection; Intra-Abdominal Infections; Blood Stream Infections; Clostridium Difficile Infections; Acute Bacterial Skin And
Skin Structure Infections; Hospital Acquired Bacterial Pneumonia; Acquired Bacterial Pneumonia; Other Diseases
2) By Drug Class: Oxazolidinones; Lipoglycopeptides; Tetracyclines; Cephalosporins; Combination Therapies; Other Drug Classes
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
North America was the largest region in the multidrug-resistant bacteria market in 2023. The regions covered in multidrug-resistant bacteria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13044&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of infectious diseases is expected to propel the growth of the multidrug-resistant bacteria market going forward. Infectious diseases refer to illnesses brought on by harmful microorganisms, such as bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are closely associated with infectious diseases due to their ability to cause infections that are difficult to treat using conventional antibiotics. These bacteria have developed resistance to multiple antibiotics, making them less susceptible to the medications commonly used to combat bacterial infections. For instance, in July 2022, according to data released by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, the number of notifiable infectious diseases in Australia increased from 289,013 in 2020 to 701,820 in 2021. Therefore, the increasing prevalence of infectious diseases will drive the multidrug-resistant bacteria market.
Key Industry Players
Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.
The multidrug resistant bacteria market report table of contents includes:
1. Executive Summary
2. Multidrug Resistant Bacteria Market Characteristics
3. Multidrug Resistant Bacteria Market Trends And Strategies
4. Multidrug Resistant Bacteria Market – Macro Economic Scenario
5. Global Multidrug Resistant Bacteria Market Size and Growth
.
.
.
26. South America Multidrug Resistant Bacteria Market
27. Brazil Multidrug Resistant Bacteria Market
28. Middle East Multidrug Resistant Bacteria Market
29. Africa Multidrug Resistant Bacteria Market
30. Multidrug Resistant Bacteria Market Competitive Landscape And Company Profiles
Top Major Players:
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Plasma powder is a protein-rich ingredient derived from the spray-drying of plasma,…
Overview and Scope A pedestrian bridge is a constructed framework spanning a railway, river, or…
Overview and Scope Next-generation antibody therapeutics are advanced antibody-based drugs in structure, functionality, and therapeutic…
Overview and Scope A neurological biomarker is a substance that provides objective and quantifiable information…
Overview and Scope Home insurance is a policy that pays for expenses and damage to…
Overview and Scope Extended-release drugs are a dosage form made to release the medication over…